nach oben

Neurosurgical Review

Erschienen in:

24.08.2017 | Review

Pathogenesis of peri-tumoral edema in intracranial meningiomas

verfasst von: Moncef Berhouma, Timothee Jacquesson, Emmanuel Jouanneau, François Cotton

Erschienen in: Neurosurgical Review | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Peri-tumoral edema in intracranial meningiomas occurs frequently and obviously impacts the morbidity and mortality of these predominantly benign neoplasms. Several causative factors (age, gender, volume, location…) have been unsuccessfully investigated. Despite recent progresses in metabolic imaging and molecular biology, the pathogenesis of peri-tumoral edema remains debated. Hypotheses include vascular endothelial growth factor, metalloproteinases and interleukins among many others. It is probable that this pathogenesis encompasses all these factors with different levels. The current review aims to shed the light on the investigated factors involved in the pathogenesis of peri-tumoral edema in meningiomas and identify the potential therapeutic targets.

Alaywan M, Sindou M (1993) Prognostic factors in the surgery for intracranial meningioma. Role of the tumoral size and arterial vascularization originating from the pia mater. Study of 150 cases. Neurochirurgie 39:337–347PubMed

Alguacil-Garcia A, Pettigrew NM, Sima AA (1986) Secretory meningioma. A distinct subtype of meningioma. Am J Surg Pathol 10:102–111PubMedCrossRef

Arienta C, Caroli M, Crotti F, Villani R (1990) Treatment of intracranial meningiomas in patients over 70 years old. Acta Neurochir 107:47–55PubMedCrossRef

Barresi V (2011) Angiogenesis in meningiomas. Brain Tumor Pathol 28:99–106. https://doi.org/10.1007/s10014-010-0012-2 PubMedCrossRef

Barresi V, Alafaci C, Caffo M, Barresi G, Tuccari G (2012) Clinicopathological characteristics, hormone receptor status and matrix metallo-proteinase-9 (MMP-9) immunohistochemical expression in spinal meningiomas. Pathol Res Pract 208:350–355. https://doi.org/10.1016/j.prp.2012.02.013 PubMedCrossRef

Beltran E, Matiasek K, De Risio L, de Stefani A, Feliu-Pascual AL, Matiasek LA (2013) Expression of MMP-2 and MMP-9 in benign canine rostrotentorial meningiomas is not correlated to the extent of peritumoral edema. Vet Pathol 50:1091–1098. https://doi.org/10.1177/0300985813481610 PubMedCrossRef

Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591–1598PubMed

Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH (1993) Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153–159. https://doi.org/10.1172/JCI116165 PubMedPubMedCentralCrossRef

Bitzer M, Opitz H, Popp J, Morgalla M, Gruber A, Heiss E, Voigt K (1998) Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor. Acta Neurochir 140:333–340PubMedCrossRef

10.

Bitzer M, Topka H, Morgalla M, Friese S, Wöckel L, Voigt K (1998) Tumor-related venous obstruction and development of peritumoral brain edema in meningiomas. Neurosurgery 42:730–737PubMedCrossRef

11.

Bitzer M, Wöckel L, Luft AR, Wakhloo AK, Petersen D, Opitz H, Sievert T, Ernemann U, Voigt K (1997) The importance of pial blood supply to the development of peritumoral brain edema in meningiomas. J Neurosurg 87:368–373. https://doi.org/10.3171/jns.1997.87.3.0368 PubMedCrossRef

12.

Bitzer M, Wöckel L, Morgalla M, Keller C, Friese S, Heiss E, Meyermann R, Grote E, Voigt K (1997) Peritumoural brain oedema in intracranial meningiomas: influence of tumour size, location and histology. Acta Neurochir 139:1136–1142PubMedCrossRef

13.

Black P, Carroll R, Zhang J (1996) The molecular biology of hormone and growth factor receptors in meningiomas. Acta Neurochir Suppl 65:50–53PubMed

14.

Black PM, Carroll R, Glowacka D, Riley K, Dashner K (1994) Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg 81:388–393. https://doi.org/10.3171/jns.1994.81.3.0388 PubMedCrossRef

15.

Bø L, Mørk SJ, Nyland H (1992) An immunohistochemical study of mononuclear cells in meningiomas. Neuropathol Appl Neurobiol 18:548–558PubMedCrossRef

16.

Borg SA, Kerry KE, Royds JA, Battersby RD, Jones TH (2005) Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells. Eur J Endocrinol 152:293–300. https://doi.org/10.1530/eje.1.01843 PubMedCrossRef

17.

Boyle-Walsh E, Hashim IA, Speirs V, Fraser WD, White MC (1994) Interleukin-6 (IL-6) production and cell growth of cultured human ameningiomas:-interactions with interleukin-1 beta (IL-1 beta) and interleukin-4 (IL-4) in vitro. Neurosci Lett 170:129–132PubMedCrossRef

18.

Bradac GB, Ferszt R, Bender A, Schörner W (1986) Peritumoral edema in meningiomas. A radiological and histological study. Neuroradiology 28:304–312PubMedCrossRef

19.

Bradac GB, Riva A, Giordana MT, Sales S, Bergui M (1997) A case of meningioma with exceptionally extensive oedema. Neuroradiology 39:273–275PubMedCrossRef

20.

Brösicke N, Faissner A (2015) Role of tenascins in the ECM of gliomas. Cell Adhes Migr 9:131–140. https://doi.org/10.1080/19336918.2014.1000071 CrossRef

21.

Carroll RS, Schrell UM, Zhang J, Dashner K, Nomikos P, Fahlbusch R, Black PM (1996) Dopamine D1, dopamine D2, and prolactin receptor messenger ribonucleic acid expression by the polymerase chain reaction in human meningiomas. Neurosurgery 38:367–375PubMedCrossRef

22.

Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270PubMedCrossRef

23.

Chang C-Y, Li M-C, Liao S-L, Huang Y-L, Shen C-C, Pan H-C (2005) Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 12:930–933. https://doi.org/10.1016/j.jocn.2004.11.017 PubMedCrossRef

24.

Chernov MF, Nakaya K, Kasuya H, Kato K, Ono Y, Yoshida S, Nakamura R, Suzuki T, Muragaki Y, Iseki H, Kubo O, Hori T, Takakura K (2009) Metabolic alterations in the peritumoral brain in cases of meningiomas: 1H-MRS study. J Neurol Sci 284:168–174. https://doi.org/10.1016/j.jns.2009.05.015 PubMedCrossRef

25.

Chiquet-Ehrismann R (1995) Tenascins, a growing family of extracellular matrix proteins. Experientia 51:853–862PubMedCrossRef

26.

Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1095PubMedCrossRef

27.

Curtis MW, Johnson KR, Wheelock MJ (2008) E-cadherin/catenin complexes are formed cotranslationally in the endoplasmic reticulum/Golgi compartments. Cell Commun Adhes 15:365–378. https://doi.org/10.1080/15419060802460748 PubMedPubMedCentralCrossRef

28.

Dharmalingam P, Roopesh Kumar VR, Verma SK (2013) Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma. Indian J Pathol Microbiol 56:349–354. https://doi.org/10.4103/0377-4929.125286 PubMedCrossRef

29.

Dimitriadou V, Rouleau A, Trung Tuong MD, Newlands GJ, Miller HR, Luffau G, Schwartz JC, Garbarg M (1997) Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. Neuroscience 77:829–839PubMedCrossRef

30.

Ding Y-S, Wang H-D, Tang K, Hu Z-G, Jin W, Yan W (2008) Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci 38:344–351PubMed

31.

Djindjian M, Caron JP, Athayde AA, Février MJ (1988) Intracranial meningiomas in the elderly (over 70 years old). A retrospective study of 30 surgical cases. Acta Neurochir 90:121–123PubMedCrossRef

32.

Domingo Z, Rowe G, Blamire AM, Cadoux-Hudson TA (1998) Role of ischaemia in the genesis of oedema surrounding meningiomas assessed using magnetic resonance imaging and spectroscopy. Br J Neurosurg 12:414–418PubMedCrossRef

33.

Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR (1991) Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 174:1275–1278PubMedCrossRef

34.

Epari S, Sharma MC, Sarkar C, Garg A, Gupta A, Mehta VS (2006) Chordoid meningioma, an uncommon variant of meningioma: a clinicopathologic study of 12 cases. J Neuro-Oncol 78:263–269. https://doi.org/10.1007/s11060-005-9092-y CrossRef

35.

Gadient RA, Otten UH (1997) Interleukin-6 (IL-6)—a molecule with both beneficial and destructive potentials. Prog Neurobiol 52:379–390PubMedCrossRef

36.

Gilbert JJ, Paulseth JE, Coates RK, Malott D (1983) Cerebral edema associated with meningiomas. Neurosurgery 12:599–605PubMedCrossRef

37.

Gilfillan AM, Austin SJ, Metcalfe DD (2011) Mast cell biology: introduction and overview. Adv Exp Med Biol 716:2–12. https://doi.org/10.1007/978-1-4419-9533-9_1 PubMedPubMedCentralCrossRef

38.

Girgis H, Palmier B, Croci N, Soustrat M, Plotkine M, Marchand-Leroux C (2013) Effects of selective and non-selective cyclooxygenase inhibition against neurological deficit and brain oedema following closed head injury in mice. Brain Res 1491:78–87. https://doi.org/10.1016/j.brainres.2012.10.049 PubMedCrossRef

39.

Go KG, Wilmink JT, Molenaar WM (1988) Peritumoral brain edema associated with meningiomas. Neurosurgery 23:175–179PubMedCrossRef

40.

Goldman CK, Bharara S, Palmer CA, Vitek J, Tsai JC, Weiss HL, Gillespie GY (1997) Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 40:1269–1277PubMedCrossRef

41.

Gray F, Bélec L, Chrétien F, Dubreuil-Lemaire ML, Ricolfi F, Wingertsmann L, Poron F, Gherardi R (1998) Acute, relapsing brain oedema with diffuse blood-brain barrier alteration and axonal damage in the acquired immunodeficiency syndrome. Neuropathol Appl Neurobiol 24:209–216PubMedCrossRef

42.

Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, Gutmann DH, Evans J, Leonard JR, Zipfel GJ, Chicoine MR (2013) Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 74:136–141. https://doi.org/10.1055/s-0033-1338262 PubMedPubMedCentralCrossRef

43.

Héron A, Dubayle D (2013) A focus on mast cells and pain. J Neuroimmunol 264:1–7. https://doi.org/10.1016/j.jneuroim.2013.09.018 PubMedCrossRef

44.

Holmin S, Söderlund J, Biberfeld P, Mathiesen T (1998) Intracerebral inflammation after human brain contusion. Neurosurgery 42:291–299PubMedCrossRef

45.

Hou J, Kshettry VR, Selman WR, Bambakidis NC (2013) Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor–directed therapy. Neurosurg Focus 35:E2. https://doi.org/10.3171/2013.8.FOCUS13301 PubMedCrossRef

46.

Huang Q, Zhao S-L, Tian X-Y, Li B, Li Z (2013) Increased co-expression of macrophage migration inhibitory factor and matrix metalloproteinase 9 is associated with tumor recurrence of meningioma. Int J Med Sci 10:276–285. https://doi.org/10.7150/ijms.5185 PubMedPubMedCentralCrossRef

47.

Inamura T, Nishio S, Takeshita I, Fujiwara S, Fukui M (1992) Peritumoral brain edema in meningiomas—influence of vascular supply on its development. Neurosurgery 31:179–185PubMedCrossRef

48.

Ingraham FD, Matson DD, McLAURIN RL (1952) Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. N Engl J Med 246:568–571. https://doi.org/10.1056/NEJM195204102461502 PubMedCrossRef

49.

Ishiyama N, Ikura M (2012) The three-dimensional structure of the cadherin-catenin complex. Subcell Biochem 60:39–62. https://doi.org/10.1007/978-94-007-4186-7_3 PubMedCrossRef

50.

Iwado E, Ichikawa T, Kosaka H, Otsuka S, Kambara H, Tamiya T, Kondo S, Date I (2012) Role of VEGF and matrix metalloproteinase-9 in peritumoral brain edema associated with supratentorial benign meningiomas. Neuropathology 32:638–646. https://doi.org/10.1111/j.1440-1789.2012.01312.x PubMedCrossRef

51.

Jabini R, Moradi A, Afsharnezhad S, Ayatollahi H, Behravan J, Raziee HR, Mosaffa F (2014) Pathodiagnostic parameters and evaluation of O⁶-methyl guanine methyl transferase gene promoter methylation in meningiomas. Gene 538:348–353. https://doi.org/10.1016/j.gene.2013.12.039 PubMedCrossRef

52.

Javerzat S, Auguste P, Bikfalvi A (2002) The role of fibroblast growth factors in vascular development. Trends Mol Med 8:483–489PubMedCrossRef

53.

Jensen RL (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neuro-Oncol 92:317–335. https://doi.org/10.1007/s11060-009-9827-2 CrossRef

54.

Jones N, Iljin K, Dumont DJ, Alitalo K (2001) Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2:257–267. https://doi.org/10.1038/35067005 PubMedCrossRef

55.

Jones NR, Rossi ML, Gregoriou M, Hughes JT (1990) Epidermal growth factor receptor expression in 72 meningiomas. Cancer 66:152–155PubMedCrossRef

56.

Jones TH, Justice SK, Timperley WR, Royds JA (1997) Effect of interleukin-1 and dexamethasone on interleukin-6 production and growth in human meningiomas. J Pathol 183:460–468. https://doi.org/10.1002/(SICI)1096-9896(199712)183:4<460::AID-PATH961>3.0.CO;2-Z PubMedCrossRef

57.

Jung S, Moon K-S, Kim S-T, Ryu H-H, Lee Y-H, Jeong Y-I, Jung T-Y, Kim I-Y, Kim K-K, Kang S-S (2007) Increased expression of intracystic matrix metalloproteinases in brain tumors: relationship to the pathogenesis of brain tumor-associated cysts and peritumoral edema. J Clin Neurosci 14:1192–1198. https://doi.org/10.1016/j.jocn.2006.11.009 PubMedCrossRef

58.

Kalkanis SN, Carroll RS, Zhang J, Zamani AA, Black PM (1996) Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas. J Neurosurg 85:1095–1101. https://doi.org/10.3171/jns.1996.85.6.1095 PubMedCrossRef

59.

Kiliç T, Bayri Y, Ozduman K, Acar M, Diren S, Kurtkaya O, Ekinci G, Buğra K, Sav A, Ozek MM, Pamir MN (2002) Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape. Neurosurgery 51:183–192PubMedCrossRef

60.

Kishimoto T (1989) The biology of interleukin-6. Blood 74:1–10PubMed

61.

Klatzo I (1985) Brain oedema following brain ischaemia and the influence of therapy. Br J Anaesth 57:18–22PubMedCrossRef

62.

Klatzo I (1987) Pathophysiological aspects of brain edema. Acta Neuropathol 72:236–239PubMedCrossRef

63.

Klatzo I (1994) Evolution of brain edema concepts. Acta Neurochir Suppl (Wien) 60:3–6

64.

Kuratsu JI, Seto H, Kochi M, Ushio Y (1994) Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma. Acta Neurochir 131:289–293PubMedCrossRef

65.

Lambertz N, Hindy NE, Adler C, Rump K, Adamzik M, Keyvani K, Bankfalvi A, Siffert W, Erol Sandalcioglu I, Bachmann HS (2013) Expression of aquaporin 5 and the AQP5 polymorphism A(-1364)C in association with peritumoral brain edema in meningioma patients. J Neuro-Oncol 112:297–305. https://doi.org/10.1007/s11060-013-1064-z CrossRef

66.

Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M (2000) Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46:938–948PubMed

67.

Le Rhun E, Taillibert S, Chamberlain MC (2016) Systemic therapy for recurrent meningioma. Expert Rev Neurother. https://doi.org/10.1080/14737175.2016.1184087

68.

Lee K-J, Joo W-I, Rha H-K, Park H-K, Chough J-K, Hong Y-K, Park C-K (2008) Peritumoral brain edema in meningiomas: correlations between magnetic resonance imaging, angiography, and pathology. Surg Neurol 69:350–355; discussion 355. https://doi.org/10.1016/j.surneu.2007.03.027 PubMedCrossRef

69.

Liao H, Bu W, Wang T-H, Ahmed S, Xiao Z-C (2005) Tenascin-R plays a role in neuroprotection via its distinct domains that coordinate to modulate the microglia function. J Biol Chem 280:8316–8323. https://doi.org/10.1074/jbc.M412730200 PubMedCrossRef

70.

Lieu AS, Howng SL (2000) Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res 38:45–52PubMedCrossRef

71.

Lobato RD, Alday R, Gómez PA, Rivas JJ, Domínguez J, Cabrera A, Madero S, Ayerbe J (1996) Brain oedema in patients with intracranial meningioma. Correlation between clinical, radiological, and histological factors and the presence and intensity of oedema. Acta Neurochir (Wien) 138:485–494CrossRef

72.

Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE, McSherry F, Norfleet J, Friedman HS, Reardon DA (2012) Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neuro-Oncol 109:63–70. https://doi.org/10.1007/s11060-012-0861-0 CrossRef

73.

Lowy CM, Oskarsson T (2015) Tenascin C in metastasis: a view from the invasive front. Cell Adhes Migr 9:112–124. https://doi.org/10.1080/19336918.2015.1008331 CrossRef

74.

Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC (1999) Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 44:732–741PubMedCrossRef

75.

Machein MR, Plate KH (2000) VEGF in brain tumors. J Neuro-Oncol 50:109–120CrossRef

76.

Maiuri F, Gangemi M, Cirillo S, Delehaye L, Gallicchio B, Carandente M, Giamundo A (1987) Cerebral edema associated with meningiomas. Surg Neurol 27:64–68PubMedCrossRef

77.

Mantle RE, Lach B, Delgado MR, Baeesa S, Bélanger G (1999) Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning. J Neurosurg 91:375–383. https://doi.org/10.3171/jns.1999.91.3.0375 PubMedCrossRef

78.

Markovic M, Antunovic V, Milenkovic S, Zivkovic N (2013) Prognostic value of peritumoral edema and angiogenesis in intracranial meningioma surgery. J BUON 18:430–436PubMed

79.

Marmarou A, Takagi H, Shulman K (1980) Biomechanics of brain edema and effects on local cerebral blood flow. Adv Neurol 28:345–358PubMed

80.

Maruo N, Morita I, Shirao M, Murota S (1992) IL-6 increases endothelial permeability in vitro. Endocrinology 131:710–714. https://doi.org/10.1210/endo.131.2.1639018 PubMedCrossRef

81.

Modrego PJ, Boned B, Berlanga JJ, Serrano M (2008) Plasmatic B-type natriuretic peptide and C-reactive protein in hyperacute stroke as markers of CT-evidence of brain edema. Int J Med Sci 5:18–23PubMedPubMedCentralCrossRef

82.

Muccioli G, Ghè C, Faccani G, Lanotte M, Forni M, Ciccarelli E (1997) Prolactin receptors in human meningiomas: characterization and biological role. J Endocrinol 153:365–371PubMedCrossRef

83.

Nakano T, Asano K, Miura H, Itoh S, Suzuki S (2002) Meningiomas with brain edema: radiological characteristics on MRI and review of the literature. Clin Imaging 26:243–249PubMedCrossRef

84.

Nakasu S, Fukami T, Jito J, Matsuda M (2005) Microscopic anatomy of the brain-meningioma interface. Brain Tumor Pathol 22:53–57. https://doi.org/10.1007/s10014-005-0187-0 PubMedCrossRef

85.

Nassehi D (2013) Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. Dan Med J 60:B4626PubMed

86.

Nassehi D, Dyrbye H, Andresen M, Thomsen C, Juhler M, Laursen H, Broholm H (2011) Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. APMIS 119:831–843. https://doi.org/10.1111/j.1600-0463.2011.02764.x PubMedCrossRef

87.

Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neuro-Oncol 109:187–193. https://doi.org/10.1007/s11060-012-0886-4 CrossRef

88.

Ng WH, Hy JW, Tan WL, Liew D, Lim T, Ang BT, Ng I (2009) Aquaporin-4 expression is increased in edematous meningiomas. J Clin Neurosci 16:441–443. https://doi.org/10.1016/j.jocn.2008.04.028 PubMedCrossRef

89.

Nguyen TH, Neil CJ, Sverdlov AL, Mahadavan G, Chirkov YY, Kucia AM, Stansborough J, Beltrame JF, Selvanayagam JB, Zeitz CJ, Struthers AD, Frenneaux MP, Horowitz JD (2011) N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy. Am J Cardiol 108:1316–1321. https://doi.org/10.1016/j.amjcard.2011.06.047 PubMedCrossRef

90.

Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M (1998) Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol 96:453–462PubMedCrossRef

91.

Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244:309–315. https://doi.org/10.1007/s00417-004-1087-4 PubMedCrossRef

92.

Nordqvist AC, Smurawa H, Mathiesen T (2001) Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg 95:839–844. https://doi.org/10.3171/jns.2001.95.5.0839 PubMedCrossRef

93.

Paek SH, Kim C-Y, Kim YY, Park IA, Kim MS, Kim DG, Jung H-W (2002) Correlation of clinical and biological parameters with peritumoral edema in meningioma. J Neuro-Oncol 60:235–245CrossRef

94.

Paek SH, Kim DG, Park C-K, Phi JH, Kim YY, Im SY, Kim JE, Park S-H, Jung H-W (2006) The role of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in microcystic meningiomas. Oncol Rep 16:49–56PubMedCrossRef

95.

Park K-J, Kang S-H, Chae Y-S, Yu M-O, Yoo M-O, Cho T-H, Suh J-K, Lee H-K, Chung Y-G (2010) Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg 112:73–80. https://doi.org/10.3171/2009.4.JNS09158 PubMedCrossRef

96.

Pas J, Wyszko E, Rolle K, Rychlewski L, Nowak S, Zukiel R, Barciszewski J (2006) Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol 38:1594–1602. https://doi.org/10.1016/j.biocel.2006.03.017 PubMedCrossRef

97.

Pepper MS (1997) Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8:21–43PubMedCrossRef

98.

Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, Wiestler OD (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109–117PubMedCrossRef

99.

Pistolesi S, Fontanini G, Camacci T, De Ieso K, Boldrini L, Lupi G, Padolecchia R, Pingitore R, Parenti G (2002) Meningioma-associated brain oedema: the role of angiogenic factors and pial blood supply. J Neuro-Oncol 60:159–164CrossRef

100.

Polyzoidis S, Koletsa T, Panagiotidou S, Ashkan K, Theoharides TC (2015) Mast cells in meningiomas and brain inflammation. J Neuroinflammation 12:170. https://doi.org/10.1186/s12974-015-0388-3 PubMedPubMedCentralCrossRef

101.

Prat R, Banzo J, Díaz FJ (1997) Somatostatin receptors in meningioma: diagnostic and therapeutic value. Rev Neurol 25:2002–2005PubMed

102.

Preston-Martin S (1996) Epidemiology of primary CNS neoplasms. Neurol Clin 14:273–290PubMedCrossRef

103.

Probst-Cousin S, Villagran-Lillo R, Lahl R, Bergmann M, Schmid KW, Gullotta F (1997) Secretory meningioma: clinical, histologic, and immunohistochemical findings in 31 cases. Cancer 79:2003–2015PubMedCrossRef

104.

Puchner MJA, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U (2010) Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 21:2445–2446. https://doi.org/10.1093/annonc/mdq634 PubMedCrossRef

105.

Regelsberger J, Hagel C, Emami P, Ries T, Heese O, Westphal M (2009) Secretory meningiomas: a benign subgroup causing life-threatening complications. Neuro-Oncology 11:819–824. https://doi.org/10.1215/15228517-2008-109 PubMedPubMedCentralCrossRef

106.

Reiss-Zimmermann M, Streitberger K-J, Sack I, Braun J, Arlt F, Fritzsch D, Hoffmann K-T (2015) High resolution imaging of viscoelastic properties of intracranial tumours by multi-frequency magnetic resonance elastography. Clin Neuroradiol 25:371–378. https://doi.org/10.1007/s00062-014-0311-9 PubMedCrossRef

107.

Reszec J, Hermanowicz A, Kochanowicz J, Turek G, Mariak Z, Chyczewski L (2012) Mast cells evaluation in meningioma of various grades. Folia Histochem Cytobiol 50:542–546. https://doi.org/10.5603/14744 PubMedCrossRef

108.

Reszec J, Hermanowicz A, Rutkowski R, Bernaczyk P, Mariak Z, Chyczewski L (2013) Evaluation of mast cells and hypoxia inducible factor-1 expression in meningiomas of various grades in correlation with peritumoral brain edema. J Neuro-Oncol 115:119–125. https://doi.org/10.1007/s11060-013-1208-1 CrossRef

109.

Reszec J, Hermanowicz A, Rutkowski R, Turek G, Mariak Z, Chyczewski L (2015) Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. Biomed Res Int 2015:e646853. https://doi.org/10.1155/2015/646853 CrossRef

110.

Ribatti D, Crivellato E (2012) Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta 1822:2–8. https://doi.org/10.1016/j.bbadis.2010.11.010 PubMedCrossRef

111.

Ricci R, Bacci A, Tugnoli V, Battaglia S, Maffei M, Agati R, Leonardi M (2007) Metabolic findings on 3T 1H-MR spectroscopy in peritumoral brain edema. AJNR Am J Neuroradiol 28:1287–1291. https://doi.org/10.3174/ajnr.A0564 PubMedCrossRef

112.

Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045–1054. https://doi.org/10.1016/S1474-4422(06)70625-1 PubMedCrossRef

113.

Rixen D, Siegel JH (2000) Metabolic correlates of oxygen debt predict posttrauma early acute respiratory distress syndrome and the related cytokine response. J Trauma 49:392–403PubMedCrossRef

114.

Rohringer M, Sutherland GR, Louw DF, Sima AA (1989) Incidence and clinicopathological features of meningioma. J Neurosurg 71:665–672. https://doi.org/10.3171/jns.1989.71.5.0665 PubMedCrossRef

115.

Rossi ML, Cruz Sanchez F, Hughes JT, Esiri MM, Coakham HB (1988) Immunocytochemical study of the cellular immune response in meningiomas. J Clin Pathol 41:314–319PubMedPubMedCentralCrossRef

116.

Roth P, Happold C, Weller M (2015) Corticosteroid use in neuro-oncology: an update. Neurooncol Pract 2:6–12. https://doi.org/10.1093/nop/npu029 PubMedCrossRef

117.

Roth P, Regli L, Tonder M, Weller M (2013) Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Rev Anticancer Ther 13:1319–1325. https://doi.org/10.1586/14737140.2013.852473 PubMedCrossRef

118.

Ruggieri F, Gemma M, Calvi MR, Nicelli E, Agarossi A, Beretta L (2012) Perioperative serum brain natriuretic peptide and cardiac troponin in elective intracranial surgery. Neurocrit Care 17:395–400. https://doi.org/10.1007/s12028-012-9684-2 PubMedCrossRef

119.

Ruggieri F, Noris A, Beretta L, Mortini P, Gemma M (2016) Serum B-type natriuretic peptide is affected by neoplastic edema in patients with a brain tumor. World Neurosurg 85:193–196. https://doi.org/10.1016/j.wneu.2015.08.074 PubMedCrossRef

120.

Saija A, Princi P, Lanza M, Scalese M, Aramnejad E, De Sarro A (1995) Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 56:775–784PubMedCrossRef

121.

Salokorpi N, Yrjänä S, Tuominen H, Karttunen A, Heljasvaara R, Pihlajaniemi T, Heikkinen E, Koivukangas J (2013) Expression of VEGF and collagen XVIII in meningiomas: correlations with histopathological and MRI characteristics. Acta Neurochir. https://doi.org/10.1007/s00701-013-1699-8

122.

Salpietro FM, Alafaci C, Lucerna S, Iacopino DG, Todaro C, Tomasello F (1994) Peritumoral edema in meningiomas: microsurgical observations of different brain tumor interfaces related to computed tomography. Neurosurgery 35:638–642PubMedCrossRef

123.

Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M (1995) Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55:1189–1193PubMed

124.

Shamah SM, Alberta JA, Giannobile WV, Guha A, Kwon YK, Carroll RS, Black PM, Stiles CD (1997) Detection of activated platelet-derived growth factor receptors in human meningioma. Cancer Res 57:4141–4147PubMed

125.

Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ (2008) Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol 70:471–477; discussion 477. https://doi.org/10.1016/j.surneu.2008.03.006 PubMedCrossRef

126.

Sindou MP, Alaywan M (1998) Most intracranial meningiomas are not cleavable tumors: anatomic-surgical evidence and angiographic predictibility. Neurosurgery 42:476–480PubMedCrossRef

127.

Smith HP, Challa VR, Moody DM, Kelly DL (1981) Biological features of meningiomas that determine the production of cerebral edema. Neurosurgery 8:428–433PubMedCrossRef

128.

Stevens JM, Ruiz JS, Kendall BE (1983) Observations on peritumoral oedema in meningioma. Part II: mechanisms of oedema production. Neuroradiology 25:125–131PubMedCrossRef

129.

Tan WL, Wong JHY, Liew D, Ng IHB (2004) Aquaporin-4 is correlated with peri-tumoural oedema in meningiomas. Ann Acad Med Singap 33:S87–S89PubMed

130.

Tanaka M, Imhof HG, Schucknecht B, Kollias S, Yonekawa Y, Valavanis A (2006) Correlation between the efferent venous drainage of the tumor and peritumoral edema in intracranial meningiomas: superselective angiographic analysis of 25 cases. J Neurosurg 104:382–388. https://doi.org/10.3171/jns.2006.104.3.382 PubMedCrossRef

131.

Tanaka T, Kishimoto T (2014) The biology and medical implications of interleukin-6. Cancer Immunol Res 2:288–294. https://doi.org/10.1158/2326-6066.CIR-14-0022 PubMedCrossRef

132.

Tena-Suck ML, Collado-Ortìz MA, Salinas-Lara C, García-López R, Gelista N, Rembao-Bojorquez D (2010) Chordoid meningioma: a report of ten cases. J Neuro-Oncol 99:41–48. https://doi.org/10.1007/s11060-009-0097-9 CrossRef

133.

Theoharides TC, Stewart JM, Panagiotidou S, Melamed I (2016) Mast cells, brain inflammation and autism. Eur J Pharmacol 778:96–102. https://doi.org/10.1016/j.ejphar.2015.03.086 PubMedCrossRef

134.

Tirakotai W, Mennel H-D, Celik I, Hellwig D, Bertalanffy H, Riegel T (2006) Secretory meningioma: immunohistochemical findings and evaluation of mast cell infiltration. Neurosurg Rev 29:41–48. https://doi.org/10.1007/s10143-005-0402-9 PubMedCrossRef

135.

Todo T, Adams EF, Rafferty B, Fahlbusch R, Dingermann T, Werner H (1994) Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth. J Neurosurg 81:394–401. https://doi.org/10.3171/jns.1994.81.3.0394 PubMedCrossRef

136.

Trittmacher S, Traupe H, Schmid A (1988) Pre- and postoperative changes in brain tissue surrounding a meningioma. Neurosurgery 22:882–885PubMedCrossRef

137.

Trott G, Pereira-Lima JFS, Leães CGS, Ferreira NP, Barbosa-Coutinho LM, Oliveira MC (2015) Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence. Braz J Med Biol Res 48:415–419. https://doi.org/10.1590/1414-431X20144163 PubMedPubMedCentralCrossRef

138.

Tsai JC, Hsiao YY, Teng LJ, Shun CT, Chen CT, Goldman CK, Kao MC (1999) Regulation of vascular endothelial growth factor secretion in human meningioma cells. J Formos Med Assoc 98:111–117PubMed

139.

Vignes JR, Sesay M, Rezajooi K, Gimbert E, Liguoro D (2008) Peritumoral edema and prognosis in intracranial meningioma surgery. J Clin Neurosci 15:764–768. https://doi.org/10.1016/j.jocn.2007.06.001 PubMedCrossRef

140.

de Vries J, Wakhloo AK (1993) Cerebral oedema associated with WHO-I, WHO-II, and WHO-III-meningiomas: correlation of clinical, computed tomographic, operative and histological findings. Acta Neurochir 125:34–40PubMedCrossRef

141.

Wang D-J, Xie Q, Gong Y, Wang Y, Cheng H-X, Mao Y, Zhong P, Huang F-P, Zheng K, Wang Y-F, Bao W-M, Yang B-J, Chen H, Xie L-Q, Zheng M-Z, Tang H-L, Zhu H-D, Chen X-C, Zhou L-F (2013) Secretory meningiomas: clinical, radiological and pathological findings in 70 consecutive cases at one institution. Int J Clin Exp Pathol 6:358–374PubMedPubMedCentral

142.

Wang P, Ni RY, Chen MN, Mou KJ, Mao Q, Liu YH (2011) Expression of aquaporin-4 in human supratentorial meningiomas with peritumoral brain edema and correlation of VEGF with edema formation. Genet Mol Res 10:2165–2171. https://doi.org/10.4238/vol10-3gmr1212 PubMedCrossRef

143.

Wijdicks EF, Schievink WI, Burnett JC (1997) Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage. J Neurosurg 87:275–280. https://doi.org/10.3171/jns.1997.87.2.0275 PubMedCrossRef

144.

Yamada S, Taoka T, Nakagawa I, Nishimura F, Motoyama Y, Park YS, Nakase H, Kichikawa K (2013) A magnetic resonance imaging technique to evaluate tumor-brain adhesion in meningioma: brain-surface motion imaging. World Neurosurg. https://doi.org/10.1016/j.wneu.2013.02.015

145.

Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K (2000) Recurrence of meningiomas. Cancer 89:1102–1110PubMedCrossRef

146.

Yoshioka H, Hama S, Taniguchi E, Sugiyama K, Arita K, Kurisu K (1999) Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer 85:936–944PubMedCrossRef

147.

Zagzag D, Friedlander DR, Dosik J, Chikramane S, Chan W, Greco MA, Allen JC, Dorovini-Zis K, Grumet M (1996) Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 56:182–189PubMed

148.

Zhou K, Wang G, Wang Y, Jin H, Yang S, Liu C (2010) The potential involvement of E-cadherin and beta-catenins in meningioma. PLoS One 5:e11231. https://doi.org/10.1371/journal.pone.0011231 PubMedPubMedCentralCrossRef

Titel: Pathogenesis of peri-tumoral edema in intracranial meningiomas
verfasst von: Moncef Berhouma
Timothee Jacquesson
Emmanuel Jouanneau
François Cotton
Publikationsdatum: 24.08.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Neurosurgical Review / Ausgabe 1/2019
Print ISSN: 0344-5607
Elektronische ISSN: 1437-2320
DOI: https://doi.org/10.1007/s10143-017-0897-x

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Risk factors for shunt dependency in patients suffering from spontaneous, non-aneurysmal subarachnoid hemorrhage

Surgery versus stereotactic radiosurgery for the treatment of multiple meningiomas in neurofibromatosis type 2: illustrative case and systematic review

Does the subspecialty of an intensive care unit (ICU) has an impact on outcome in patients suffering from aneurysmal subarachnoid hemorrhage?

Endoscopic management of third ventricular colloid cysts in mildly dilated lateral ventricles

Spinal Meningiomas Prognostic Evaluation Score (SPES): predicting the neurological outcomes in spinal meningioma surgery

The segmentation of the posterior cerebral artery: a microsurgical anatomic study

Update Chirurgie